Sustained local delivery of siRNA from an injectable scaffold

Biomaterials

Volumn 33, Issue 4, 2012, Pages 1154-1161

  Nelson, Christopher E ^a   Gupta, Mukesh K ^a   Adolph, Elizabeth J ^a   Shannon, Joshua M ^a   Guelcher, Scott A ^a   Duvall, Craig L ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Controlled release; Drug delivery; Polyurethane; RAFT; RNA interference; Tissue engineering

Indexed keywords

CONTROLLED RELEASE; DOSE-DEPENDENT; GENE SILENCING; GENE SILENCING TECHNOLOGY; IN-VITRO; INJECTABLE POLYURETHANES; LOCAL DELIVERY; MICELLAR NANOPARTICLES; MOUSE-FIBROBLASTS; NANO PARTICULATES; PH-RESPONSIVE; PLATFORM TECHNOLOGY; RAFT; RESEARCH TOOLS; RNA INTERFERENCE; TISSUE DEFECTS; TISSUE REGENERATION; TISSUE SCAFFOLDS;

CELL CULTURE; DRUG DELIVERY; GENE THERAPY; GENETIC ENGINEERING; POLYURETHANES; RNA; TISSUE; TISSUE ENGINEERING;

SCAFFOLDS (BIOLOGY);

2 PROPYL ACRYLIC ACID; 4 CYANO 4 (ETHYLSULFANYLTHIOCARBONYL)SULFANYLPENTANOIC ACID; LYSINE TRIISOCYANATE; NANOPARTICLE; POLY(DEXTRO LACTIDE); POLY(GLYCOLIDE); POLYCAPROLACTONE; POLYMER; POLYOL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG STABILITY; DRUG UPTAKE; GENE DELIVERY SYSTEM; GENE SILENCING; MOUSE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ANIMALS; DELAYED-ACTION PREPARATIONS; HYDROGEN-ION CONCENTRATION; INJECTIONS; MICE; NANOPARTICLES; NIH 3T3 CELLS; POLYURETHANES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TISSUE SCAFFOLDS;

EID: 81355161728     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.033     Document Type: Article

References (58)

1. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 1998, 391:806-811.
2. Kaiser P.K., Symons R.C., Shah S.M., Quinlan E.J., Tabandeh H., Do D.V., et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010, 150:33-39. e2.
3. Leachman S.A., Hickerson R.P., Schwartz M.E., Bullough E.E., Hutcherson S.L., Boucher K.M., et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010, 18:442-446.
4. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
5. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009, 6:659-668.
6. Ribas A., Zuckerman J.E., Hsueh T., Koya R.C., Davis M.E. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol 2011, 131:453-460.
7. Yao Y., Wang C., Varshney R.R., Wang D.A. Antisense makes sense in engineered regenerative medicine. Pharm Res 2009, 26:263-275.
8. White P.J. Barriers to successful delivery of short interfering RNA after systemic administration. Clin Exp Pharmacol Physiol 2008, 35:1371-1376.
9. Gao K., Huang L. Nonviral methods for siRNA delivery. Mol Pharm 2009, 6:651-658.
10. Agrawal A., Min D.H., Singh N., Zhu H., Birjiniuk A., von Maltzahn G., et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano 2009, 3:2495-2504.
11. Convertine A.J., Benoit D.S., Duvall C.L., Hoffman A.S., Stayton P.S. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release 2009, 133:221-229.
12. Jafari M., Chen P. Peptide mediated siRNA delivery. Curr Top Med Chem 2009, 9:1088-1097.
13. Lee J.S., Green J.J., Love K.T., Sunshine J., Langer R., Anderson D.G. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett 2009, 9:2402-2406.
14. Nishina K., Unno T., Uno Y., Kubodera T., Kanouchi T., Mizusawa H., et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008, 16:734-740.
15. Qi L., Gao X. Quantum dot-amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA. ACS Nano 2008, 2:1403-1410.
16. Watanabe K., Harada-Shiba M., Suzuki A., Gokuden R., Kurihara R., Sugao Y., et al. In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia. Mol Biosyst 2009, 5:1306-1310.
17. Wu S.Y., McMillan N.A. Lipidic systems for in vivo siRNA delivery. AAPS J 2009, 11:639-652.
18. Xia C.F., Boado R.J., Pardridge W.M. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm 2009, 6:747-751.
19. Ghosn B., Kasturi S.P., Roy K. Enhancing polysaccharide-mediated delivery of nucleic acids through functionalization with secondary and tertiary amines. Curr Top Med Chem 2008, 8:331-340.
20. Moad G., Chiefari J., Chong Y.K., Ercole F., Krstina J., Jeffery J., et al. Living free-radical polymerization by reversible addition-fragmentation chain transfer: the RAFT process. Macromolecules 1998, 31:5559-5562.
21. Boyer C., Bulmus V., Davis T.P., Ladmiral V., Liu J., Perrier S. Bioapplications of RAFT polymerization. Chem Rev 2009, 109:5402-5436.
22. Convertine A.J., Diab C., Prieve M., Paschal A., Hoffman A.S., Johnson P.H., et al. pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules 2010, 11:2904-2911.
23. Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z., Kay M.A., Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA 2004, 10:766-771.
24. Dykxhoorn D.M., Palliser D., Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006, 13:541-552.
25. Krebs M.D., Jeon O., Alsberg E. Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels. J Am Chem Soc 2009, 131:9204-9206.
26. Vinas-Castells R., Holladay C., di Luca A., Diaz V.M., Pandit A. Snail1 down-regulation using small interfering RNA complexes delivered through collagen scaffolds. Bioconjug Chem 2009, 20:2262-2269.
27. Nguyen P.D., Tutela J.P., Thanik V.D., Knobel D., Allen R.J., Chang C.C., et al. Improved diabetic wound healing through topical silencing of p53 is associated with augmented vasculogenic mediators. Wound Repair Regen 2010, 18:553-559.
28. Lee J.W., Tutela J.P., Zoumalan R.A., Thanik V.D., Nguyen P.D., Varjabedian L., et al. Inhibition of Smad3 expression in radiation-induced fibrosis using a novel method for topical transcutaneous gene therapy. Arch Otolaryngol 2010, 136:714-719.
29. Rujitanaroj P.O., Wang Y.C., Wang J., Chew S.Y. Nanofiber-mediated controlled release of siRNA complexes for long term gene-silencing applications. Biomaterials 2011, 32:5915-5923.
30. Guelcher S.A. Biodegradable polyurethanes: synthesis and applications in regenerative medicine. Tissue Eng Part B Rev 2008, 14:3-17.
31. Guan J., Stankus J.J., Wagner W.R. Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J Control Release 2007, 120:70-78.
32. Nelson D.M., Baraniak P.R., Ma Z., Guan J., Mason N.S., Wagner W.R. Controlled release of IGF-1 and HGF from a biodegradable polyurethane scaffold. Pharm Res 2011, 28:1282-1293.
33. Li B., Yoshii T., Hafeman A.E., Nyman J.S., Wenke J.C., Guelcher S.A. The effects of rhBMP-2 released from biodegradable polyurethane/microsphere composite scaffolds on new bone formation in rat femora. Biomaterials 2009, 30:6768-6779.
34. Li B., Davidson J.M., Guelcher S.A. The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds. Biomaterials 2009, 30:3486-3494.
35. Li B., Brown K.V., Wenke J.C., Guelcher S.A. Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model. J Control Release 2010, 145:221-230.
36. Hafeman A.E., Zienkiewicz K.J., Zachman A.L., Sung H.J., Nanney L.B., Davidson J.M., et al. Characterization of the degradation mechanisms of lysine-derived aliphatic poly(ester urethane) scaffolds. Biomaterials 2011, 32:419-429.
37. Adolph EJ, Hafeman A, Davidson J, Nanney L, Guelcher S. Injectable polyurethane composite scaffolds delay wound contraction and support cellular infiltration and remodeling in rat excisional wounds. J Biomed Mater Res A, in press.
38. Hafeman A.E., Li B., Yoshii T., Zienkiewicz K., Davidson J.M., Guelcher S.A. Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration. Pharm Res 2008, 25:2387-2399.
39. Moad G., Chong Y.K., Postma A., Rizzardo E., Thang S.H. Advances in RAFT polymerization: the synthesis of polymers with defined end-groups. Polymer 2005, 46:8458-8468.
40. Ferrito M., Tirrell D.A. Poly(2-ethylacrylic acid). Macromol Synth 1992, 11:59-62.
41. Guelcher S.A., Patel V., Gallagher K.M., Connolly S., Didier J.E., Doctor J.S., et al. Synthesis and in vitro biocompatibility of injectable polyurethane foam scaffolds. Tissue Eng 2006, 12:1247-1259.
42. Guelcher S., Srinivasan A., Hafeman A., Gallagher K., Doctor J., Khetan S., et al. Synthesis, in vitro degradation, and mechanical properties of two-component poly(ester urethane)urea scaffolds: effects of water and polyol composition. Tissue Eng 2007, 13:2321-2333.
43. Papadopoulou V., Kosmidis K., Vlachou M., Macheras P. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm 2006, 309:44-50.
44. Duvall C.L., Convertine A.J., Benoit D.S., Hoffman A.S., Stayton P.S. Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. Mol Pharm 2010, 7:468-476.
45. Siepmann J., Peppas N.A. Higuchi equation: derivation, applications, use and misuse. Int J Pharm 2011, 418:6-12.
46. Barone F., Cellai L., Matzeu M., Mazzei F., Pedone F. DNA, RNA and hybrid RNA-DNA oligomers of identical sequence: structural and dynamic differences. Biophys Chem 2000, 86:37-47.
47. Akhtar S., Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007, 117:3623-3632.
48. Medina-Kauwe L.K., Xie J., Hamm-Alvarez S. Intracellular trafficking of nonviral vectors. Gene Ther 2005, 12:1734-1751.
49. Cho Y.W., Kim J.D., Park K. Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol 2003, 55:721-734.
50. van der Aa M.A., Huth U.S., Hafele S.Y., Schubert R., Oosting R.S., Mastrobattista E., et al. Cellular uptake of cationic polymer-DNA complexes via caveolae plays a pivotal role in gene transfection in COS-7 cells. Pharm Res 2007, 24:1590-1598.
51. Jones R.A., Cheung C.Y., Black F.E., Zia J.K., Stayton P.S., Hoffman A.S., et al. Poly(2-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles. Biochem J 2003, 372:65-75.
52. El-Sayed M.E., Hoffman A.S., Stayton P.S. Rational design of composition and activity correlations for pH-sensitive and glutathione-reactive polymer therapeutics. J Control Release 2005, 101:47-58.
53. Thomas J.L., Barton S.W., Tirrell D.A. Membrane solubilization by a hydrophobic polyelectrolyte: surface activity and membrane binding. Biophys J 1994, 67:1101-1106.
54. Thomas J.L., Tirrell D.A. Polyelectrolyte-sensitized phospholipid-vesicles. Acc Chem Res 1992, 25:336-342.
55. Borden K.A., Eum K.M., Langley K.H., Tirrell D.A. Interactions of synthetic-polymers with cell-membranes + model membrane systems. 13. On the mechanism of polyelectrolyte-induced structural reorganization in thin molecular films. Macromolecules 1987, 20:454-456.
56. Hoffman A.S., Lackey C.A., Press O.W., Stayton P.S. A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex. Bioconjug Chem 2002, 13:996-1001.
57. Krebs M.D., Alsberg E. Localized, targeted, and sustained siRNA delivery. Chemistry 2011, 17:3054-3062.
58. Lei Y., Rahim M., Ng Q., Segura T. Hyaluronic acid and fibrin hydrogels with concentrated DNA/PEI polyplexes for local gene delivery. J Control Release 2011, 153:255-261.